Table 2 Indicators of policy and pharmaceutical systems used for the review

Policy

 1. % of countries with a current (updated in the last 2 years) essential medicines list (EML)

 2. % of countries with an EML that includes tracer RMNCH medicines^a

 3. % of countries with RMNCH tracer medicines in standard treatment guidelines (STGs)

 4. % of countries where RMNCH tracer medicines in the STG are also on the EML^a

 5. % of countries with a national policy on the use of community management of pneumonia

 6. % of countries with a national policy on the use of community management of diarrhea

Regulatory

 7. % of countries where tracer medicines have at least one product registered for use in country^a

 8. % of countries where quality problems are reported

 9. % of countries where medicines (including RMNCH medicines) products are routinely sampled for quality testing

Procurement

 10. % of countries where RMNCH commodities are procured centrally ^a

Financing

 11. % of countries with a costed MNCH plan

 12. % of countries with fees for services in the public sector

 13. % of countries with fees for services where women and children under 5 are exempt from paying for RMNCH services or medicines

 14. % of countries with a policy to provide RMNCH commodities free of charge in public sector ^a

Supply Chain Management

 15. % of countries with a pull (demand-based) distribution method to health facilities

 16. % of countries with stock outs of RMNCH tracer products reported at CMS in last 3 years^a

Information systems

 17. % of countries with a logistics management information system (LMIS) to track stock-level/consumption of medicines (paper, electronic, or mobile)

 18. % of countries where all tracer RMNCH commodities are included in LMIS^a